The Experts below are selected from a list of 134304 Experts worldwide ranked by ideXlab platform
Beth Scott - One of the best experts on this subject based on the ideXlab platform.
-
masters of Marketing bringing private sector skills to public health partnerships
American Journal of Public Health, 2007Co-Authors: Valerie Curtis, Nana Garbrahaidoo, Beth ScottAbstract:Skill in Marketing is a scarce resource in public health, especially in developing countries. The Global Public-Private Partnership for Handwashing with Soap set out to tap the Consumer Marketing skills of industry for national handwashing programs. Lessons learned from commercial marketers included how to (1) understand Consumer motivation, (2) employ 1 single unifying idea, (3) plan for effective reach, and (4) ensure effectiveness before national launch. After the first Marketing program, 71% of Ghanaian mothers knew the television ad and the reported rates of handwashing with soap increased. Conditions for the expansion of such partnerships include a wider appreciation of what Consumer Marketing is, what it can do for public health, and the potential benefits to industry. Although there are practical and philosophical difficulties, there are many opportunities for such partnerships.
-
Ethics in public health research: masters of Marketing: bringing private sector skills to public health partnerships.
American journal of public health, 2007Co-Authors: Val Curtis, Nana Garbrah-aidoo, Beth ScottAbstract:Skill in Marketing is a scarce resource in public health, especially in developing countries. The Global Public-Private Partnership for Handwashing with Soap set out to tap the Consumer Marketing skills of industry for national handwashing programs. Lessons learned from commercial marketers included how to (1) understand Consumer motivation, (2) employ 1 single unifying idea, (3) plan for effective reach, and (4) ensure effectiveness before national launch. After the first Marketing program, 71% of Ghanaian mothers knew the television ad and the reported rates of handwashing with soap increased. Conditions for the expansion of such partnerships include a wider appreciation of what Consumer Marketing is, what it can do for public health, and the potential benefits to industry. Although there are practical and philosophical difficulties, there are many opportunities for such partnerships.
Susan Baker - One of the best experts on this subject based on the ideXlab platform.
-
CRM in the context of new Consumer Marketing
Interactive Marketing, 2003Co-Authors: Susan BakerAbstract:This paper describes the characteristics of the IT-enabled post-modern Consumer and goes on to suggest that, as an organisational response to this, CRM can only be viable in a very limited space, where perceived market granularity is high and where the value proposition is highly flexible. This paper draws on the work of two research groups currently running at Cranfield School of Management: the New Marketing Research Group (www.new-Marketing.org) and the Cranfield CRM Research Forum (www.cranfield-crm.org).
-
New Consumer Marketing: Managing a Living Demand System
2003Co-Authors: Susan Baker, Margrit BassAbstract:Foreword.Acknowledgements.About the Author. Introduction.1. Earthquake!2. The New Consumer.3. Concerns of Brand Owners and Retailers.4. New Consumer Marketing.5. A Model of New Consumer Marketing.6. Value Definition.7. Value Creation.8. Value Delivery.9. Demand System Management.Notes.References.Index.
Ajay E. Kuriyan - One of the best experts on this subject based on the ideXlab platform.
-
Assessing "Cell Therapy" Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States.
Ophthalmology, 2019Co-Authors: Rajinder S. Nirwan, Thomas A. Albini, Jayanth Sridhar, Harry W. Flynn, Ajay E. KuriyanAbstract:Purpose “Cell therapy” is becoming increasingly available to the public via online direct-to-Consumer advertisement within the United States (U.S.). The current study investigates the scope of “cell therapy” clinics across the U.S. that advertise and offer “cell therapy” for ocular conditions based on information provided on their websites. Design Cross-sectional study. Participants The study included companies that are U.S.-based, participate in direct-to-Consumer online Marketing, have websites that can be data-mined with content analysis, and advertise therapy for ocular conditions. Methods Using a systematic, extensive keyword-based Internet search, content analysis of company websites was utilized to identify, document, and analyze U.S. businesses Marketing “cell therapy” for ocular conditions as of September 16, 2017. Main Outcome Measures Clinic locations, source of stem cells used, route of administration, marketed ocular conditions, and cost of treatment. Results Forty companies with 76 clinics use “cell therapy” to treat ocular conditions. California (23), Florida (12), and Illinois (10) contain the most clinics. All 40 companies specified sources of cells, which included autologous adipose-derived stem cells (35; 67%), autologous bone marrow–derived stem cells (8; 15%), amniotic stem cells (2; 4%), peripheral blood–derived stem cells (2; 4%), umbilical cord blood stem cells (2; 4%), allogenic bone marrow–derived stem cells (1; 2%), placental stem cells (1; 2%), and xenocells (1; 2%). The most commonly marketed ocular conditions included macular degeneration (35), optic neuritis (18), retinitis pigmentosa (17), and diabetic retinopathy (16). The most common routes of administration were intravenous (22) and “unspecified” (12); however, other companies listed more ocular-specific routes such as intravitreal injections (2), retrobulbar injections (2), eye injections (2), retrofundal injection (1), sub-Tenon injection (1), intraocular injection with vitrectomy (1), and eye drops (1). The cost of advertised “cell therapy” ranged from $4000 to $10 500. Conclusions “Cell therapy” for ocular conditions is readily available via direct-to-Consumer Marketing strategies across the United States. The “cells” are harvested from numerous sources and administered through different methods for multiple ocular conditions at these “cell therapy” clinics. Limited data for these treatments necessitates advocating caution to physicians and patients about treatments offered at commercial “cell therapy” clinics.
Mark Uncles - One of the best experts on this subject based on the ideXlab platform.
-
The first decade: emerging issues of the twenty‐first century in Consumer Marketing
Journal of Consumer Marketing, 2011Co-Authors: David R. Fortin, Mark UnclesAbstract:Purpose – As one rewinds the clock to the early days of the twenty‐first century, it can be quite surprising to realise how much the Consumer landscape has changed from what it is today. This paper aims to introduce the special issue and attempts to take stock of the last decade and reflect on the transformation of key areas of the changing marketplace and its impact on consumption.Design/methodology/approach – A critical and integrative appraisal of emerging issues in Consumer Marketing is used to develop a framework for reviewing the relationship between demand‐side and supply‐side trends in the Consumer landscape.Findings – In reviewing major developments and trends of the last decade, the paper argues that the consumption landscape now operates in a rapidly changing environment that can be characterised as both turbulent and disruptive. These major shifts are emerging from the physical environment, technological innovation and the transformation of major markets. In all these scenarios, significant ev...
Douglas Sipp - One of the best experts on this subject based on the ideXlab platform.
-
Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments.
Clinical pharmacology and therapeutics, 2017Co-Authors: Zubin Master, D. Paciulli, Douglas SippAbstract:The direct-to-Consumer Marketing of unproven stem cell interventions (SCIs) is a serious public health concern. Regulations and education have had modest impact, indicating that different actors must play a role to stop this unfettered market. We consider the role of the biotech industry in tackling unproven SCIs. Grounded in the concept of corporate social responsibility, we argue that biotech companies should screen Consumers to ensure that products and services are being used appropriately and educate employees about unproven SCIs.